Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Venkata K. Jayanti"'
Publikováno v:
Journal of Clinical Oncology. 30:61-61
61 Background: The global incidence of HCC is over 700,000 patients making it the sixth leading cancer. Recently new drugs have been approved to treat HCC. Nevertheless, prognosis is poor with a 5 year survival of 11%. Hence, it is important to under
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7703fceb5e1b34e61f7af80c15149135
https://doi.org/10.1200/jco.2012.30.34_suppl.61
https://doi.org/10.1200/jco.2012.30.34_suppl.61
Autor:
Venkata K Jayanti, Glen I. Misek
Publikováno v:
Journal of Clinical Oncology. 30:e14640-e14640
e14640 Background: The global incidence of HCC is over 700,000 patients making it the sixth leading cancer and the prognosis is poor with a 5 year survival of 11%. It is important to understand if there are differences in survival based on the presen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::180b304d8eddccf281caae4784f8541d
https://doi.org/10.1200/jco.2012.30.15_suppl.e14640
https://doi.org/10.1200/jco.2012.30.15_suppl.e14640
Publikováno v:
Pharmaceutical Research; Sep2004, Vol. 21 Issue 9, p1622-1630, 9p